Huizinga, Tom W. J. http://orcid.org/0000-0001-7033-7520
Torii, Yoshifumi
Muniz, Rafael http://orcid.org/0000-0003-2696-6500
Clinical trials referenced in this document:
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
https://doi.org/10.1136/rmdopen-2019-000987
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.2220
Documents that mention this clinical trial
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
https://doi.org/10.1136/rmdopen-2019-000987
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Biosimilars for the treatment of psoriasis
https://doi.org/10.1080/14712598.2019.1636963
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
https://doi.org/10.1136/annrheumdis-2016-210459
FRI0645 EVALUATION OF MARKETED KITS FOR MEASUREMENT OF ABP 501, THE FIRST APPROVED ADALIMUMAB BIOSIMILAR, DRUG CONCENTRATION AND ANTI-DRUG ANTIBODY LEVELS IN PATIENT SERUM
https://doi.org/10.1136/annrheumdis-2019-eular.6361
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.6746
FRI0115 Indirect standardised assessment of injection site pain following subcutaneous administration of citrate-free formulation of adalimumab and its biosimilar abp 501
https://doi.org/10.1136/annrheumdis-2018-eular.6595
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study (Results)
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra)
https://doi.org/10.1136/annrheumdis-2017-eular.3405
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
FRI0087 EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)
https://doi.org/10.1136/annrheumdis-2019-eular.960
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Biosimilars for the treatment of psoriasis
https://doi.org/10.1080/14712598.2019.1636963
Documents that mention this clinical trial
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Biosimilars: considerations for clinical practice
https://doi.org/10.1136/conmed-2017-100005
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-001096
Documents that mention this clinical trial
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
THU0198 Immunogenicity associated with a transition from adalimumab reference product to abp 501 in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.7225
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
https://doi.org/10.1136/annrheumdis-2016-210459
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.6746
Biosimilars: considerations for clinical practice
https://doi.org/10.1136/conmed-2017-100005
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
https://doi.org/10.1136/annrheumdis-2017-212245
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Biosimilars: considerations for clinical practice
https://doi.org/10.1136/conmed-2017-100005
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-001096
Documents that mention this clinical trial
FRI0088 SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.4220
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
Documents that mention this clinical trial
AB0285 RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP PHARMACOKINETIC STUDY OF PF-06410293, AN ADALIMUMAB BIOSIMILAR, BY SUBCUTANEOUS DOSING USING A PREFILLED SYRINGE OR A PREFILLED PEN IN HEALTHY SUBJECTS
https://doi.org/10.1136/annrheumdis-2020-eular.454
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
https://doi.org/10.1136/rmdopen-2021-001578
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2022-002423
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
https://doi.org/10.1007/s40744-020-00259-8
AB0289 EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26
https://doi.org/10.1136/annrheumdis-2020-eular.279
Funding for this research was provided by:
Mylan Inc
Article History
Received: 5 October 2020
Accepted: 12 November 2020
First Online: 1 December 2020